Collaboration aims to develop innovative machine learning and artificial intelligence solutions for personalized and earlier treatment in neurology
_256_384.jpg)
In Japan, breast cancer is the most common cancer in women, with approximately 92,000 cases of breast cancer diagnosed in 2020
The company will manufacture a cancer immunotherapy product from 2022
The investment will establish additional capacity across the entire global value chain from manufacturing of active pharmaceutical ingredients (API) to assembly and packaging, with the vast majority being invested in API capacity
The group now has 325 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Under this scheme, the company will make a committed investment in plant and machinery, get incentives on incremental sales of pharmaceutical products
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
Saroglitazar Mg is an investigational compound in the USA, and is yet to be approved by the U.S. Food & Drug Administration (USFDA) or European Medicines Agency (EMA)
The setting up of these 8 plants will lead to a total committed investment of Rs. 260.40 crore
Both companies will combine their expertise to channel real-world evidence toward ground-breaking new treatments in rare diseases
Subscribe To Our Newsletter & Stay Updated
